← All trials
NCT00268814
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2002
- Primary completion
- Dec 1, 2003
- Completion date
- Dec 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 1015
- Arms / groups
- 8 / —
- Source
- AACT · pre-existing
Sponsors
- University of HamburgLead sponsor
- City of BonnCollaborator
- University of HamburgOverall official - principal investigator
- University of HamburgStudy director
- Federal Ministry of Health, GermanyCollaborator
- State of Northrhine-WestfaliaCollaborator
- State of HessenCollaborator
- State of Lower-SaxonyCollaborator
- City of HamburgCollaborator
- City of HanoverCollaborator
- City of FrankfurtCollaborator
- City of CologneCollaborator
- City of MunichCollaborator
- University of HamburgReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.